GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Endo International PLC (OTCPK:ENDPQ) » Definitions » Interest Coverage
中文

Endo International (Endo International) Interest Coverage : 313.49 (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Endo International Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Endo International's Operating Income for the three months ended in Dec. 2023 was $80 Mil. Endo International's Interest Expense for the three months ended in Dec. 2023 was $-0 Mil. Endo International's interest coverage for the quarter that ended in Dec. 2023 was 313.49. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Endo International PLC has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Endo International's Interest Coverage or its related term are showing as below:

ENDPQ' s Interest Coverage Range Over the Past 10 Years
Min: 0.9   Med: 1.01   Max: 385.38
Current: 385.38


ENDPQ's Interest Coverage is ranked better than
88.29% of 692 companies
in the Drug Manufacturers industry
Industry Median: 11.925 vs ENDPQ: 385.38

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Endo International Interest Coverage Historical Data

The historical data trend for Endo International's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Endo International Interest Coverage Chart

Endo International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.08 1.19 1.40 0.92 385.38

Endo International Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.69 395.55 543.30 251.35 313.49

Competitive Comparison of Endo International's Interest Coverage

For the Drug Manufacturers - Specialty & Generic subindustry, Endo International's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Endo International's Interest Coverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Endo International's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Endo International's Interest Coverage falls into.



Endo International Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Endo International's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Endo International's Interest Expense was $-1 Mil. Its Operating Income was $382 Mil. And its Long-Term Debt & Capital Lease Obligation was $4 Mil.

Interest Coverage=-1* Operating Income (A: Dec. 2023 )/Interest Expense (A: Dec. 2023 )
=-1*381.914/-0.991
=385.38

Endo International's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Endo International's Interest Expense was $-0 Mil. Its Operating Income was $80 Mil. And its Long-Term Debt & Capital Lease Obligation was $4 Mil.

Interest Coverage=-1* Operating Income (Q: Dec. 2023 )/Interest Expense (Q: Dec. 2023 )
=-1*79.626/-0.254
=313.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Endo International  (OTCPK:ENDPQ) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Endo International Interest Coverage Related Terms

Thank you for viewing the detailed overview of Endo International's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Endo International (Endo International) Business Description

Traded in Other Exchanges
Address
Simmonscourt Road, Ballsbridge, First Floor, Minerva House, Dublin, IRL, 4
Endo International PLC is a specialty pharmaceutical company with a considerable presence in pain management, urology, orthopedics, endocrinology, bariatrics, and others. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company generates maximum revenue from the Branded Pharmaceuticals segment. Some of its products include XIAFLEX, SUPPRELIN, PERCOCET, TESTOPEL, VASOSTRICT, ADRENALIN, and APLISOL.
Executives
James Patrick Tursi officer: Executive VP, Global R&D 106 ASHLEY COURT, MOORESTOWN NJ 08057
Frank B. Raciti officer: VP, Controller and CAO C/O ENDO HEALTH SOLUTIONS INC., 1400 ATWATER DRIVE, MALVERN PA 19355
Shane Cooke director TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
William P Montague director
Jennifer M Chao director 7 PURITAN WOODS ROAD, RYE NY 10580
George Apostol officer: EVP, Head of Global R&D C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN 4 L2 00000
Mary Christine Smith director 3658 50TH AVE NE, SEATTLE WA 98105
Mark T. Bradley officer: EVP, Chief Financial Officer C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Mark G Barberio director 19 WIK STREET, WILLIAMSVILLE NY 14221
Jack D. Boyle officer: SVP, Interim Controller C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Roger H Kimmel director LATHAM & WATKINS, 885 THIRD AVENUE, NEW YORK NY 10022
Domenico Ciarico officer: EVP & Chief Commercial Officer C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Rahul Garella officer: EVP, Intl Pharmaceuticals C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Carrie Ann Nichol officer: VP, Controller & CAO 927 GRANDVIEW DRIVE, EXTON PA 19341

Endo International (Endo International) Headlines

From GuruFocus